Related Experiment Video
Updated: Aug 6, 2026

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
CHAF1A promotes RAD51 loading and homologous recombination to drive tumor radioresistance
Ruru Wang1, Yao Hou1,2, Jie Zhang1
1High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Chinese Academy of Sciences; Anhui Province Key Laboratory of Environmental Toxicology and Pollution Control Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Abstract:
Aberrant activation of DNA damage repair (DDR) pathways drives therapeutic resistance in cancer. Although Chromatin Assembly Factor 1 subunit A (CHAF1A) is well characterized for its role in chromatin assembly, its specific function in the DNA damage response has remained poorly defined. Here, we demonstrate that CHAF1A functions as a key regulator of DNA repair and radioresistance. Upon DNA double-strand breaks, CHAF1A is rapidly recruited to damage sites in an ATM-associated manner. Intriguingly, CHAF1A recruitment further enhances ATM phosphorylation and amplifies the DNA damage signal. Consequently, depletion of CHAF1A compromises the efficiency of both homologous recombination (HR) and non-homologous end joining (NHEJ). Mechanistically, CHAF1A governs repair pathway utilization in a cell cycle-dependent manner: during S phase, CHAF1A interacts with RAD51 in collaboration with PCNA, promoting the loading of RAD51 at DNA damage sites; whereas in non-S-phase cells, CHAF1A preferentially promotes the recruitment of KU70 to support NHEJ. Functionally, silencing CHAF1A markedly enhances tumor radiosensitivity, as robustly validated in cell-derived xenograft models and supported by proof-of-concept evidence from a patient-derived xenograft model. Collectively, our findings establish CHAF1A as a pivotal regulator of DNA damage repair in lung cancer models and position it as a promising therapeutic target for overcoming radioresistance.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Treatment Resistant Cancers
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
